Halozyme Therapeutics, Inc. 1 Forward-Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance and growth rates (including the Company's 2026 financial guidance and longer term financial outlook through 2028 and the assumptions used in deriving such guidance and longer term financial outlook) including expectations for futu ...

Collaborations and Partnerships - Halozyme Therapeutics has collaborations and licensing agreements with major biopharmaceutical companies including Roche, Takeda, and Pfizer, generating revenues from sales-based milestone payments and royalties from ten commercial products [254]. - In April 2025, Janssen received European Commission approval for the SC formulation of RYBREVANT with ENHANZE, marking the tenth partnered product commercialized [266]. - Takeda announced the approval of HYQVIA SC with ENHANZE for chronic inflammatory demyelinating polyneuropathy treatment in June 2025 [266]. Technology and Product Development - Halozyme's ENHANZE technology facilitates subcutaneous drug delivery, improving patient experience by reducing treatment burden and enabling fixed-dose administration [253]. - The company reported that the ongoing argenx ARGX-121 Phase 1 program was expanded to include a subcutaneous arm evaluating ARGX-121 with ENHANZE in healthy adults [258]. - The company has developed auto-injector products with Teva and is collaborating with McDermott Laboratories on further auto-injector development programs [256]. - In December 2025, Halozyme received approval from the National Medical Products Administration in China for RYBREVANT FASPRO for advanced non-small cell lung cancer treatment [258]. Financial Performance - Total royalties increased by 52% to $867.8 million in 2025 from $571.0 million in 2024, driven by strong sales of ENHANZE partner products, particularly VYVGART Hytrulo, which saw a 444% increase [269]. - Product sales, net rose by 24% to $376.4 million in 2025, with proprietary product sales increasing by 17% and bulk rHuPH20 sales up by 54% [271]. - Revenues under collaborative agreements increased by 8% to $152.3 million, primarily due to a 133% rise in sales-based milestones [272]. Expenses and Cash Flow - Total operating expenses surged by 100% to $927.6 million, largely due to a $284.9 million expense related to acquired in-process research and development [273]. - Income tax expense increased by 33% to $150.0 million, mainly due to non-deductible in-process research and development expenses [279]. - Cash, cash equivalents, and marketable securities totaled $142.8 million as of December 31, 2025, sufficient to fund operations for at least the next 12 months [281]. - Net cash provided by operating activities increased by $172.5 million to $651.6 million, attributed to higher revenue [288]. Acquisitions and Investments - The company spent $1.0 billion on acquisitions of Elektrofi and Surf Bio, contributing to a significant increase in net cash used in investing activities [290]. - A contingent liability of $23.0 million was assumed in the acquisition of Elektrofi related to future milestone payments [347]. Debt and Financing - In December 2025, Halozyme completed the sale of $750 million aggregate principal amount of 2031 and 2032 Convertible Notes to fund various strategic initiatives [268]. - The company completed the sale of $750.0 million in aggregate principal amount of 0.875% Convertible Senior Notes due 2032, with net proceeds of approximately $735.0 million after fees [294]. - The company completed the sale of $720.0 million in aggregate principal amount of 1.00% Convertible Senior Notes due 2028, with net proceeds of approximately $702.0 million after fees [309]. - The company repurchased approximately $676.8 million of its 2027 Convertible Notes, including premiums and accrued interest [322]. - The Amended Revolving Credit Facility has a total commitment of $750 million and matures on or before November 5, 2030 [328]. Risk Management - The company does not believe that a 10% change in interest rates would materially impact its results of operations based on its current investment portfolio [354]. - The company hedges a portion of foreign currency exchange risk related to forecasted royalties revenue in Swiss francs to mitigate earnings and cash flow volatility [355]. - Cash, cash equivalents, and marketable securities are assessed to have minimal risk of default or illiquidity based on discussions with investment advisors and a review of holdings [356].

HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE [Accessibility Statement] Skip NavigationFull Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billionFull Year 2025 Royalty Revenue Increased 52% YOY to Record $868 millionCompleted Acquisitions of Elektrofi's Hyperconâ"¢ Technology and Surf Bio's Hyperconcentration TechnologyReiterating 2026 Financial Guidance Ranges:Total Revenue of $1.710 - $1.810 billion, YOY Growth of 22% - 30%Adjuste ...

Core Insights - Halozyme Therapeutics, Inc. will release its fourth quarter and full year 2025 financial and operating results on February 17, 2026, after market close [1] - A conference call will be held on the same day at 1:30 PM PT/4:30 PM ET to discuss these results [1] Company Overview - Halozyme is a biopharmaceutical company focused on improving patient experiences and outcomes through innovative drug delivery solutions [1] - The company is known for its ENHANZE® drug delivery technology, which utilizes the proprietary enzyme rHuPH20 to facilitate subcutaneous delivery of drugs, impacting over one million patients globally [1] - Halozyme has partnered with major pharmaceutical companies such as Roche, Takeda, Pfizer, and others to commercialize its technology across more than 100 markets [1] Technology and Product Development - The company has expanded its drug delivery technology portfolio with Hyperconâ™ and Surf Bio's hyperconcentration technology, which aims to reduce injection volume while maintaining dosage [1] - Hyperconâ™ technology has been licensed to leading biopharmaceutical partners, enhancing the delivery of biologics subcutaneously [1] - Halozyme also develops drug-device combination products using advanced auto-injector technologies to improve patient comfort and adherence [1] Corporate Structure - Halozyme is headquartered in San Diego, California, with additional offices in Ewing, New Jersey; Minnetonka, Minnesota; and Boston, Massachusetts [1]

This Medical Technology Leader Sees Growth Into The 2040s | Investor's Business DailySPECIAL REPORT: [Find The Online Broker That Best Fits Your Needs]---Medical technology leader Halozyme Therapeutics (HALO) is this week's IBD Sector Leaders selection, having bypassed two buy points and entered a buy zone. The recent IBD Stock Of The Day is rallying after the company raised its 2025 and 2026 outlook. It also offered a bold forecast for 2027, 2028 and beyond. The biopharmaceutical company's enzyme technolog ...

Core Viewpoint - The article emphasizes the importance of investing in high-quality growth and momentum stocks that are reasonably priced, with a focus on long-term performance and potential market outperformance [1] Group 1: Investment Strategy - The investment strategy involves focusing on growth and momentum stocks that are expected to outperform the market over the long term [1] - The analyst has a history of advising investors to buy at market lows, specifically citing a recommendation in March 2009 during the financial crisis, which led to significant market gains [1] Group 2: Market Performance - From 2009 to 2019, the S&P 500 saw an increase of 367%, while the Nasdaq experienced a remarkable increase of 685%, highlighting the potential for substantial returns in the stock market [1]

Core Viewpoint - Halozyme Therapeutics is highlighted as a stock to watch, nearing a buy point with a focus on its technical analysis patterns, particularly the double bottom pattern, which is considered a positive indicator for potential investment [1]. Group 1: Stock Performance - Halozyme Therapeutics (HALO) is currently priced at $75.36, showing an increase of $0.91 or 1.22% [1]. - The stock has a composite rating of 99 out of 99, indicating strong performance relative to its peers [1]. - The company is ranked 8th out of 197 in its industry group, showcasing its competitive position [1]. Group 2: Technical Analysis - The stock is approaching a buy point at $75.59, which is identified as a critical entry point for investors [1]. - The emerging pattern of a double bottom is noted as one of the three positive chart patterns to look for in technical analysis [1]. - Halozyme's relative strength rating has seen an upgrade, indicating improved performance compared to the market [1].

Core Insights - The article highlights several stocks that are trading near buy points, with a focus on companies benefiting from data center expansion [1] Group 1: Stocks to Watch - GE Vernova (GEV) has successfully broken out past a buy point [1] - Vertiv Holdings (VRT), Dycom Industries (DY), Halozyme Therapeutics (HALO), and Viking Holdings (VIK) are also identified as stocks to watch, trading near buy points [1] - Among these, GE Vernova, Vertiv, and Dycom have reported a 35% growth in earnings per share, indicating strong performance linked to data center expansion [1] Group 2: Market Context - The article notes that the U.S. government is entering a shutdown, which may impact market conditions [1] - Despite market fluctuations, certain stocks like GE Vernova and others are highlighted for their potential as they approach key levels [1]

Core Insights - Halozyme Therapeutics, Inc. (NASDAQ:HALO) is recognized as one of the best stocks to buy for investment, highlighting its strong market position and potential for growth [1] Group 1: Analyst Ratings and Price Targets - H.C. Wainwright has reiterated a Buy rating on Halozyme, maintaining a price target of $90, reflecting confidence in the company's strategic and financial strength [2] - Morgan Stanley has slightly lowered its price target for HALO from $79 to $75 while keeping an Overweight rating, indicating a cautious but positive outlook on the stock [3] Group 2: Business Developments - Recent business developments with Takeda and Skye are viewed as significant wins for Halozyme, expanding the reach of its ENHANZE platform beyond oncology into larger markets such as inflammatory bowel disease and obesity [2] Group 3: Company Overview - Halozyme Therapeutics is a biopharmaceutical company focused on the research, development, and commercialization of proprietary enzymes and devices globally, positioning itself in a competitive industry [4]

Core Insights - Halozyme Therapeutics (HALO) shares increased nearly 4% after the release of preliminary full-year 2025 results that exceeded expectations, along with an upward revision of sales and EPS guidance for 2026 [1][6]. Financial Performance - Preliminary revenues for full-year 2025 are projected to be between $1.39 billion and $1.40 billion, reflecting a year-over-year growth of 36% to 38%, surpassing previous guidance of $1.30 billion to $1.38 billion and the Zacks Consensus Estimate of $1.35 billion [4]. - Anticipated royalty revenues for 2025 are expected to be in the range of $865 million to $870 million, indicating a year-over-year growth of 51% to 52% [5]. 2026 Guidance - For 2026, total revenues are expected to be between $1.71 billion and $1.81 billion, representing a growth of 23% to 30% over projected 2025 revenues [6]. - Royalty revenues for 2026 are now anticipated to be between $1.13 billion and $1.17 billion, implying a year-over-year growth of 30% to 35%, ahead of previous expectations of $900 million to $940 million [7]. - Adjusted earnings per share for 2026 are projected to be between $7.75 and $8.25, an increase from earlier projections of $6.50 to $7.00 [8]. Strategic Developments - The raised guidance for adjusted EBITDA and earnings per share includes a financial impact of approximately $60 million from the acquisition of Hypercon and Surf Bio technologies, which were not included in earlier guidance [9]. - By the end of 2026, the company expects to have 15 partner programs in development and aims to sign three or more new drug-delivery licensing agreements [10]. Market Performance - Over the past year, shares of Halozyme have increased by 29.1%, compared to the industry growth of 15.6% [2].